Sinopharm Group Wuhan Blood Products

Wuhan Blood Products, a subsidiary of China National Biotec Group (CNBG) under Sinopharm, is a leading Chinese biopharmaceutical company specializing in the research, development, and manufacture of plasma-derived therapies. The company operates advanced plasma fractionation facilities and manages numerous plasma collection centers to ensure a stable supply of raw materials. Its core product portfolio includes human albumin, intravenous immunoglobulin (IVIG), and various coagulation factors such as Factor VIII. These products are critical for treating conditions like hemophilia, immune deficiencies, and severe infections. As part of the larger Sinopharm ecosystem, the company plays a vital role in China's national blood product security and public health infrastructure.